Sandoz stock trades at EUR 74.52 with CHF 30.2 billion value

Published on 10/08/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morgan Stanley raised its target from CHF 55 to CHF 60 on October 6, 2026. Sandoz stock stood at EUR 74.52 on October 8, 2026.

Key points in brief

Sandoz stock was EUR 74.52 at Lang & Schwarz on October 8, 2026 at 4:38 p.m. CEST.
The company had a CHF 30.2 billion market capitalization, a 56.1 P/E ratio and a 1.0 percent dividend yield.
Morgan Stanley raised its Sandoz price target from CHF 55 to CHF 60 on October 6, 2026.
Sandoz, Novartis and Teva all traded lower on October 8, 2026, with Sandoz down 1.3 percent in SIX trading.

Sandoz, CH1243598427, Illustration mit AI erstellt.

At Lang & Schwarz, Sandoz stock was trading at EUR 74.52 on October 8, 2026 at 4:38 p.m. CEST. The quote places the company beside a CHF 30.2 billion market capitalization and a 56.1 trailing P/E ratio.

Price sits near yearly high

The SIX-listed company was quoted at CHF 69.80 on October 8, 2026, down 1.3 percent from CHF 70.74. Its 52-week range runs from CHF 47.73 to CHF 75.90, leaving the SIX price 8.12 percent below the upper end of that range.

Trading volume stood at 393,417 shares, compared with an average volume of 1,215,721 shares. The gap between actual and average activity shows a quieter session than the recent trading baseline.

Valuation and analyst targets

Sandoz carries a trailing P/E ratio of 56.1 and a dividend yield of 1.0 percent. The valuation is higher than Novartis at 21.5 times earnings, while Teva trades at 64.1 times earnings, based on the October 8, 2026 market data.

On October 6, 2026, Morgan Stanley analyst Thibault Boutherin raised the Sandoz price target from CHF 55 to CHF 60 while keeping an Underweight rating, according to Markets Insider. The new target remains below the SIX price, creating a clear contrast with the company valuation shown by the market.

Comparison with peers

Sandoz: minus 1.3 percent, P/E 56.1, market capitalization CHF 30.2 billion.

Novartis: minus 1.9 percent, P/E 21.5, market capitalization CHF 223.8 billion.

Teva: minus 1.9 percent, P/E 64.1, market capitalization USD 44.8 billion.

Next reporting date

A report published by Head Topics on October 8, 2026 identifies October 26, 2026 as the date for Sandoz third-quarter revenue updates. That date gives the next scheduled checkpoint for comparing sales momentum with the current valuation.